What China ’s Zero-COVID Policy Means for the Pandemic—in China and the Rest of the World
Protests in multiple Chinese cities over the strict COVID-19 policies enforced by China’s government reflect the growing sentiment of people around the world. We’re tired of the pandemic, and tired of the myriad ways the SARS-CoV-2 virus has changed our lives forever. But the demonstrations in China also reflect a more specific, local frustration with a strategy for controlling the virus that every other country in the world has long since left behind. China’s zero-COVID strategy is an extension of the drastic measures instituted, not only in that country but in others around the world, including the U.S....
Source: TIME: Health - December 2, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer. (Source: World Pharma News)
Source: World Pharma News - November 29, 2022 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

In new deal, AstraZeneca places small bet on'critical but challenging' target
In new deal, AstraZeneca places small bet on 'critical but challenging' target AstraZeneca has its eyes on NRF2 as a target for inflammatory and respiratory diseases, and it’s handing out $2 million in cash to pluck a preclinical candidate from a drug discovery shop. It’s so early that C4X…#readingendpoints #astrazeneca #discoveryshop #critical #challenging #target #discovery #drugdiscovery #endpoints #bet (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2022 Category: Consumer Health News Source Type: news

AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M
AstraZeneca entered into a multimillion-dollar licensing deal Monday giving it worldwide exclusive rights to develop and commercialize an oral therapy under development as a potential treatment for chronic obstructive pulmonary disease (COPD) and other inflammatory and respiratory diseases. Under the financial terms of the deal, AstraZeneca (NYSE: AZN) will make an upfront payment of $2 million to C4X Discovery Holdings (AIM: C4XD), a drug discovery company with offices in Manchester and London, … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 28, 2022 Category: Pharmaceuticals Authors: John George Source Type: news

Alexion's new U.S. head is looking for 'the next generation of medicines to unpack'
A little more than a year since its acquisition by AstraZeneca plc, Alexion Pharmaceuticals Inc. is operating in "the best of both worlds" as the official rare disease unit of the U.K. pharma giant. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 22, 2022 Category: American Health Authors: Rowan Walrath Source Type: news

Vaccines Helped to Control COVID-19. But the Global Rollout Is Still Broken
As successful as the COVID-19 vaccines have been in curbing the pandemic, their benefits haven’t been enjoyed equally by people around the globe. Throughout the pandemic—and even now—vaccine development and distribution has been undeniably lopsided, skewed in favor of developed countries with the resources to create, test, manufacture, and distribute shots when the need arises. In the third year of pandemic, while nearly 70% of people worldwide have received at least one COVID-19 vaccine dose, in low-income countries, only 24% have. In its latest report on the global vaccine market, which includes an asse...
Source: TIME: Health - November 21, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Cochrane review of COVID-19 vaccines shows they are effective
A comprehensive review of all the evidence available from randomised controlled trials of COVID 19 vaccines up to November 2021 has concluded that most protect against infection and severe or critical illness caused by the virus.The review, a collaboration of independent, international experts, also found there was little or no difference between the number of people experiencing serious side effects after vaccination compared to those who were unvaccinated.The researchers, led by Isabelle Boutron, Professor of Epidemiology at Université Paris Cit é and Director of Cochrane France, analysed published data from 41 randomi...
Source: Cochrane News and Events - November 18, 2022 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Roche signs up to the Science Based Targets initiative and the Sustainable Markets Initiative to further deepen the commitment to climate actions
Basel, 17 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it is committing to the Science Based Targets initiative (SBTi) and the Sustainable Markets Initiative (SMI) to achieve net zero for scope 1, 2 and 3 greenhouse gas emissions.Since 2004, Roche has been implementing carbon dioxide reduction measures that have led to a combined decrease of over 70% in tons of carbon dioxide per employee. By committing to achieve net-zero in line with the external framework provided by SBTi, Roche continues its successful carbon reduction journey on Scope 1 and 2 (own operations and purchased energy) and extends...
Source: Roche Investor Update - November 17, 2022 Category: Pharmaceuticals Source Type: news

AstraZeneca finally abandons plan to get Covid shot approved in the US
AstraZeneca said its application has become overcomplicated and 'very large'. Regulators refused to approve the jab amid concerns over data and fears it could cause a fatal blood clot. (Source: the Mail online | Health)
Source: the Mail online | Health - November 11, 2022 Category: Consumer Health News Source Type: news

Positive results emerge for Covid nasal spray less than month after disappointing UK trial
Less than a month after a disappointing trial for a nasal spray AstraZeneca vaccine, researchers from across the pond have been racing ahead. (Source: Daily Express - Health)
Source: Daily Express - Health - November 11, 2022 Category: Consumer Health News Source Type: news

Imfinzi and Imjudo with Chemotherapy Approved in the US for Patients with Metastatic Non-Small Cell Lung Cancer
Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy 11 November 2022 -- AstraZeneca’s Imfinzi (durvalumab) in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 11, 2022 Category: Drugs & Pharmacology Source Type: news

FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer
On November 10, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab (Imfinzi, AstraZeneca Pharmaceuticals) and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensi (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 10, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

News at a glance: A new antibiotic, COVID-19 in Antarctica, and a Venus mission deferred
CLIMATE SCIENCE Space station carbon mapper faces demise An orbiting fridge-size sensor that uses lasers to map forest structure—key to understanding how much carbon trees sequester—is set to plummet to a fiery destruction in the atmosphere in 2023 unless NASA extends its tenure. Researchers and some U.S. Congress members are lobbying the agency to reconsider its plan to jettison the Global Ecosystem Dynamics Investigation (GEDI) instrument from the International Space Station to make way for a Department of Defense sensor. GEDI measures the height of trees and the quality of habitat they provide...
Source: ScienceNOW - November 10, 2022 Category: Science Source Type: news

AstraZeneca gains from cancer treatment sales
Boost comes as drugmaker’s Covid-19 vaccine sales drop sharply (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 10, 2022 Category: Pharmaceuticals Source Type: news

AstraZeneca drops submission to US regulators for Covid-19 vaccine approval
Plan abandoned almost two years after initial approval in UK and Europe (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - November 10, 2022 Category: Pharmaceuticals Source Type: news